Appendix 4E and 2019 Full Year Results
Released
Released
Announcement PDF
®
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
28 February 2020
Appendix 4E and 2019 Full Year Results
Key Developments Achieved for MagSense™ Imaging Technology
Highlights:
• Successful completion of a GLP-compliant toxicology study demonstrating the MagSense™
imaging agent safety profile
• Received Breakthrough Device designation from the US FDA for MagSense™ for the detection
and staging of HER2 breast cancer
• Demonstrated MagSense™ targeted nanoparticles may have commercial utility with existing MRI
scanners
• Executed cost management steps to preserve capital and focus resources on planning for first
clinical study; net operating cash outflow reduced to $4.2 million (down from $6.6 million)
• Cash receipts up to $559K with a further $2 million in non-dilutive cash from R&D tax credit in Q3
• Successful $3.6 million Renounceable Rights Issue in Q4, strengthening balance sheet and
providing funds for continued development of the MagSense™ imaging agent
• Net loss after tax $3.5M, 60% improvement vs 2018 ($8.8M)
• Cash balance of $3.4M at 31 December 2019
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare
through the earlier detection of cancer, has today released its Appendix 4E and Preliminary Results for the
Full Year ended 31 December 2019.
Progress in Development of the MagSense™ Nanoparticle Imaging Agent
During 2019 Imagion has been focused on the development of its first targeted nanoparticle imaging agent
for the detection and staging of HER2 metastatic breast cancer.
Significant progress has been made towards de-risking the program and ensuring readiness to enter the
clinic, with key milestones including:
• Successful completion of the toxicology study in May 2019, strongly indicating Imagion’s
nanoparticles can be expected to be safe for use in humans, with no observable adverse effects
reported – a critical milestone to support filings with regulatory authorities to proceed to in-human
testing.
• Receipt of a Breakthrough Device designation from the US Food and Drug Administration (FDA)
for the staging of HER2 breast cancer - a program which recognises development-stage medical
device products that address a medical need where either no approved or cleared alternatives
exist or offer significant advantages over approved or cleared alternatives. The designation allows
for accelerated communication with the agency.
• Presenting results at the World Molecular Imaging Conference showing that the MagSense™
nanoparticles could be used as an MR imaging agent – creating an alternative commercial
opportunity for the company’s targeted nanoparticles in diagnostic imaging.
These key developments have been instrumental in establishing the basis for Imagion to move forward
with its first in-human study. Additionally, as recently announced, the company is now commencing
manufacturing of the nanoparticle formulation, following successful completion of the rigorous vendor
qualifications required to certify GMP manufacturing requirements can be met.
During the year Dr John Hazle, Chair of the Department of Imaging Physics at the MD Anderson Cancer
Centre, transitioned from the company’s Board of Directors to establish and Chair the company’s first
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystems.com
®
Scientific Advisory Board (SAB). The SAB brings together scientific and clinical experts from disciplines
including oncology, medical imaging, nanotechnology and clinical trial design, who will play an important
role in charting the company’s product development and commercial pathways.
2019 Financial performance
Cash receipts from customers in 2019 increased 262% year-on-year to $559K, due to an increase in cash
payments received from Israeli biotechnology company NewPhase Ltd, which is investigating the use of
Imagion’s nanoparticles in a hyperthermia-based cancer therapy product under development. In
November, a second order for $300K was placed to be recognized in 2020.
Operating cash outflows remained steady year-on-year at $6.8 million (0.4% up on 2018).
Imagion Biosystem’s cash balance stood at $3.4 million at end 2019. This cash balance was boosted by
several inflows throughout the year, including $3.6 million raised in a renounceable rights offer partially
underwritten by lead manager CPS Capital.
In July 2019 Imagion also received its first rebate of $2 million in R&D tax incentives from the Australian
Taxation Office (ATO) for its 2018 tax return after applying for the Advance/Oversees Finding under the
ATO’s R&D Tax Incentive program.
The company has recently filed its 2019 tax return, and is now pleased to report it is expecting a similar tax
refund of approximately $2 million, which it expects to receive in the second calendar quarter of 2020.
Overall Imagion’s net loss after tax improved 60% in 2019 to $3.5 million ($8.8 million net loss in 2018).
Contributing to this improvement was additional income added as a result of the R&D tax incentive and a
17% increase in revenue from operations ($433K in 2019, vs $371K in 2018).
Expenditure was also reduced as a result of prudent measures undertaken to preserve working capital,
including reducing staff by one third and a restructuring resources to focus on working with outside
collaborators as the Company advances into the clinic.
Imagion Biosystems’ Executive Chairman Bob Proulx said, “This has been a year of heavy-lifting to ensure
we are well positioned to advance to our first-in-human study. The receipt of Breakthrough Device
designation was a real highlight and underlines the transformational potential of our technology. We have
further de-risked the technology with the successful completion of toxicology studies, generation of additional
pre-clinical data and completing the necessary requirements to commence GMP manufacturing.
“The quality of our recently established Scientific Advisory Board is another testament to the growing interest
in our MagSense™ technology.
“I’d like to thank our shareholders for their support of Imagion’s rights issue in 2019, which has provided
funds to allow us to keep moving forward. We are entering an exciting new phase in 2020 as we prepare to
enter the clinic.”
For further information please visit www.imagionbiosystems.com
This Announcement has been approved by the Disclosure Committee of Imagion Biosystems Ltd.
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Australian Media & Investor Relations:
Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61-3-9866-4722
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystems.com
IMAGION BIOSYSTEMS LIMITED
PRELIMINARY REPORT AND APPENDIX 4E
FOR THE YEAR ENDED 31 DECEMBER 2019
1
1. Reporting period (“current period”):
Previous corresponding period:
Year ended 31 December 2019
Year ended 31 December 2018
2. Results for announcement to the market
Item
Movement
Revenue
(Loss) from ordinary activities after tax
attributable to members
Net (loss) for the period attributable to
members
up
down
570.28%
58.84%
to
to
2,490,000
(3,432,506)
down
58.84%
to
(3,432,506)
Amounts per share
Franked amount per share
$AUD
$AUD
-
-
Dividends
Final
Interim
Record date for determining
entitlements to dividends
$AUD
N/A
The loss for the Company after providing for income tax amounted to $3,432,506. The Company continued
with its research & development strategy during the year. The Company did not declare a dividend for the
year.
3. Consolidated Statement of Profit and Loss and Other Comprehensive Income
Refer to the attached Financial Statements together with note for the year ended 31 December 2019.
4. Consolidated Statement of Financial Position
Refer to the attached Financial Statements together with note for the year ended 31 December 2019.
5. Consolidated Statement of Cash Flows
Refer to the attached Financial Statements together with note for the year ended 31 December 2019.
6. Consolidated Statement of Changes in Equity
Refer to the attached Financial Statements together with note for the year ended 31 December 2019.
7. Dividends
Current period:
There were no dividends paid, recommended or declared during the period.
Previous period:
There were no dividends paid, recommended or declared during the previous financial period.
2
8. Dividend reinvestment plans
The dividend reinvestment plans shown below are in operation:
None
Last date for receipt of election notices for the dividend reinvestment plan:
N/A
9. Net tangible assets
31 Dec 2019
$AUD
31 Dec 2018
$AUD
0.0058
0.0120
Net tangible asset backing per ordinary
share
10. Details of entities over which control has been gained or lost
N/A
11. Details of associates and joint venture entities
N/A
12. Any other significant information
N/A
13. Foreign Entities
Details of origin of Accounting Standards used in compiling report:
Imagion Biosystems Limited owns 100% of Imagion Biosystems Inc. This company prepares their financial
statements in accordance with International Financial Reporting Standards (IFRS) as issued by the
International Accounting Standards Board (IASB).
14. Results for the period
14.1 Earnings per security
Basic earnings per share
Diluted earnings per share
Weighted average no. of ordinary shares
outstanding during the period used in the
calculation of basic EPS
3
31 Dec 2019
cents
31 Dec 2018
cents
(0.0100)
(0.0100)
(0.0378)
(0.0378)
342,221,471
220,883,627
14.2 Returns to shareholders
N/A
14.3 Significant features of operating performance
Revenue for the year ended 31 December 2019 was $2,490,000. Profit/(Loss) for the year ended 31 December
2019 was ($3,432,506). Imagion Biosystems is currently in the Research and Development phase and will
continue to complete Research and Development in the future.
14.4 Segment results
Identification of reporting operating segments
The consolidated entity is organised into one operating segment being Research & Development. This operating
segment is based on internal reports that are reviewed and used by the Board of Directors (who are identified
as the Chief Operating Decision Makers (CODM) in assessing performance and in determine the allocation of
resources.
14.5 Trends in performance
Refer to Item 2 within the Appendix 4E.
14.6 Any other factors which have affected the results in the period which are likely to affect the result in the
future, including those where the effect could not be quantified:
N/A
15. Status of Audit
The financial statements are in the process of being audited and an unqualified opinion is expected to be issued.
16. Description of any likely audit dispute or qualification:
There are no disputes or qualifications being considered by the auditors.
Signed:
Robert Proulx
Director
Dated: 28 February 2020
4
IMAGION BIOSYSTEMS LIMITED
FINANCIAL STATEMENTS – FOR THE YEAR ENDED 31 DECEMBER 2019
TABLE OF CONTENTS
Statement of Profit & Loss and other comprehensive income
2
Statement of Financial Position
3
Statement of Changes in Equity
4
Statement of Cash Flows
5
Notes to the Financial Statements
6
Imagion Biosystems Limited
Consolidated Statement of Profit and Loss and Other Comprehensive Income
For the year ended 31 December 2019
Note
2019
$
2018
$
432,714
2,057,286
2,490,000
371,489
371,489
Expenses
Research & development costs
Employee salaries and expenses
Professional fees
General expenses
Share based payments expense
Depreciation
Foreign exchange gain/(loss)
Finance costs
(2,269,006)
(2,757,564)
(784,023)
(868,684)
940,754
(141,988)
(32,837)
(9,158)
(3,295,676)
(3,128,280)
(525,302)
(1,148,459)
(837,133)
(213,791)
444,892
(7,753)
Loss before income tax expense
(3,432,506)
(8,340,013)
Income tax expense
Loss after income tax expense
(3,432,506)
(8,340,013)
(70,284)
(411,997)
-
-
(70,284)
(411,997)
(3,502,790)
(8,752,010)
(3,502,790)
(8,752,010)
Cents
Cents
(0.0100)
(0.0100)
(0.0378)
(0.0378)
Revenue
Revenue and other income
Research & development tax incentives
1
Other comprehensive income
Items that may be reclassified subsequently to profit or
loss
Foreign currency translation reserve
Income tax relating to these items
Other comprehensive income/(loss) for the year, net of
tax
Total comprehensive income/(loss) for the year
Loss attributable to:
Owners of Imagion Biosystems Limited
Loss per share attributable to the owners of
Imagion Biosystem Limited
Basic loss per share
Diluted loss per share
10
10
The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction
with the accompanying notes.
2
Imagion Biosystems Limited
Consolidated Statement of Financial Position
As at 31 December 2019
Note
2019
$
2018
$
3,401,713
71
171,112
3,572,896
4,367,097
140,481
408,021
4,915,599
434,150
865,051
1,299,201
271,860
271,860
4,872,097
5,187,459
885,979
261,760
101,832
33,990
1,283,561
1,187,992
36,082
75,723
1,299,797
615,019
615,019
18,434
18,434
Total liabilities
1,898,581
1,318,231
Net assets
2,973,517
3,869,228
36,904,580
714,478
(34,645,541)
33,182,325
1,899,938
(31,213,035)
2,973,517
3,869,228
Assets
Current assets
Cash and cash equivalents
Trade and other receivables
Other current assets
Total current assets
2
3
Non-current assets
Plant and equipment
Right-of-use assets
Total non-current assets
4
Total assets
Liabilities
Current liabilities
Trade and other payables
Lease liability
Employee benefits
Other liability
Total current liabilities
5
Non-current liabilities
Lease liability
Total non-current liabilities
Equity
Issued capital
Reserves
Accumulated losses
6
7
8
Total equity
The above consolidated statement of financial position should be read in conjunction with the accompanying notes.
3
Imagion Biosystems Limited
Consolidated Statement of Changes in Equity
As at 31 December 2019
Issued
Capital
$
Reserves
$
Accumulated
Losses
$
Total Equity
$
28,686,708
1,138,870
(22,873,022)
6,952,556
Loss after income tax expense for the year
Other comprehensive income for the year, net of tax
-
(411,997)
(8,340,013)
-
(8,340,013)
(411,997)
Total comprehensive income for the year
-
(411,997)
(8,340,013)
(8,752,010)
Transactions with owners in their capacity as owners:
Contributions of equity
Cost of contributions of equity
Share-based payments
5,146,705
(651,088)
-
1,173,065
-
5,146,705
(651,088)
1,173,065
Balance at 31 December 2018
33,182,325
1,899,938
(31,213,035)
3,869,228
Issued
Capital
$
Reserves
$
Accumulated
Losses
$
Total Equity
$
33,182,325
-
1,899,938
(70,284)
(31,213,035)
(3,432,506)
-
3,869,228
(3,432,506)
(70,284)
-
(70,284)
(3,432,506)
(3,502,790)
Transactions with owners in their capacity as owners:
Contributions of equity
Cost of contributions of equity
Transfer from reserves
Share-based payments
3,848,272
(287,033)
161,016
-
(161,016)
(954,160)
-
3,848,272
(287,033)
(954,160)
Balance at 31 December 2019
36,904,580
714,478
(34,645,541)
2,973,517
Consolidated
Balance at 1 January 2018
Consolidated
Balance at 1 January 2019
Loss after income tax expense for the year
Other comprehensive income for the year, net of tax
Total comprehensive income for the year
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.
4
Imagion Biosystems Limited
Consolidated Statement of Cash Flows
For the year ended 31 December 2019
Note
Consolidated
2019
2018
$
$
Cash flows from operating activities
Receipts from customers (inclusive of sales and other taxes)
Payments to suppliers and employees (inclusive of sales and other taxes)
Interest received
Interest and other finance costs paid
Government grants and tax incentives
558,844
(6,815,862)
16,556
(3,501)
2,061,918
154,457
(6,786,076)
67,078
(2,669)
-
(4,182,045)
(6,567,210)
Cash flows from investing activities
Payment for property, plant and equipment
(12,353)
(83,565)
Net cash used in investing activities
(12,353)
(83,565)
Cash flows from financing activities
Lease repayments
Proceeds from financing arrangements
Proceeds from the issue of shares
Proceeds from exercise of share options
Share issue costs
(120,165)
84,770
3,369,266
5,148
(13,305)
(128,493)
4,285,884
(54,189)
Net cash used in financing activities
3,325,714
4,103,202
Net increase/(decrease) in cash and cash equivalents
(868,684)
(2,547,573)
Cash and cash equivalents at the beginning of the financial year
Effects of exchange rate changes on cash and cash equivalents
4,367,097
(96,700)
Cash and cash equivalents at the end of the financial year
3,401,713
Net cash from operating activities
9
5
¤
6,872,829
41,841
4,367,097
Imagion Biosystems Limited
Notes to the Financial Statements
For the year ended 31 December 2019
Note 1. Revenue
Consolidated
2019
A$
Sales revenue
Sale of goods
Other revenue
Interest
Other income
Revenue
2018
A$
410,854
410,854
191,477
191,477
21,788
72
21,860
36,955
143,057
180,012
432,714
371,489
Consolidated
2019
A$
2018
A$
Note 2. Current assets - cash and cash equivalents
Cash on hand
Cash at bank
16
3,401,697
16
4,367,081
3,401,713
4,367,097
Balances as above
3,401,713
4,367,097
Balance as per statement of cash flows
3,401,713
4,367,097
Reconciliation to cash and cash equivalents at the end of the financial year
The above figures are reconciled to cash and cash equivalents at the end of the
financial year as shown in the statement of cash flows as follows:
Note 3. Current assets – other
Consolidated
2019
2018
A$
A$
Prepayments
Other assets
6
97,977
73,135
52,885
355,136
171,112
408,021
Imagion Biosystems Limited
Notes to the Financial Statements
For the year ended 31 December 2019
Note 4. Non-current assets - property, plant and equipment
Consolidated
2019
2018
A$
A$
Plant and equipment - at cost
Less: accumulated depreciation
1,032,534
(598,384)
1,328,260
(1,056,400)
434,150
271,860
Note 5. Current liabilities - trade and other payables
Consolidated
2019
2018
A$
A$
Trade payables
Other payables
7
708,905
177,074
983,680
204,312
885,979
1,187,992
Imagion Biosystems Limited
Notes to the Financial Statements
For the year ended 31 December 2019
Note 6. Equity - issued capital
Ordinary shares
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in
proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value
and the company does not have a limited amount of authorised capital.
2018
Shares
Ordinary shares - fully paid
Consolidated
2019
Shares
2018
A$
2019
A$
322,742,824
508,782,191
33,182,325
36,488,486
Movements in ordinary share capital
Date
Shares
Issue Price
A$
Details
Issue of shares (share-based payment)
Issue of shares (rights issue)
Issue of shares (rights issue)
Issue of shares (performance shares)
6 June 2018
24 October 2018
28 November 2018
28 November 2018
10,529,053
10,288,098
96,859,510
1,300,000
0.062
0.040
0.040
0.160
652,801
411,524
3,874,380
208,000
Sub total
31 December 2018
322,742,824
33,833,413
Costs of capital raising
Closing balance
(651,088)
33,182,325
Movements in ordinary share capital
Details
Issue of shares (performance rights)
Issue of shares (performance rights)
Issue of shares (share-based payment)
Issue of shares (exercise of options)
Issue of shares (rights issue)
Issue of shares (share-based payment)
Date
24 June 2019
30 September 2019
30 September 2019
4 October 2019
26 November 2019
10 December 2019
Shares
962,500
31,250
3,445,310
187,500
181,412,807
2,500,000
Sub total
31 December 2019
511,282,191
Issue Price
0.160
0.160
0.050
0.039
0.020
0.017
Costs of capital raising
Closing balance
A$
154,000
5,000
172,266
7,266
3,628,256
42,500
37,191,613
(287,033)
36,904,580
On 24 June 2019, 962,500 vested performance shares were converted into ordinary shares. The performance shares
were issued to current and previous employees.
On 30 September 2019, 31,250 vested performance shares were converted into ordinary shares. The performance
shares were issued to a current employee.
On 30 September 2019, the consolidated entity issued an additional 3,445,310 shares to Family Office Networks, Inc.
and nanoComposix, Inc. as payment for the consolidated entity to contractors under deeds of subscription and
settlement. The shares have been valued at the fair value on the date of issue.
On 4 October 2019, an option holder exercised 187,500 options and converted to ordinary shares.
8
Imagion Biosystems Limited
Notes to the Financial Statements
For the year ended 31 December 2019
Note 6. Equity - issued capital (continued)
The consolidated entity completed a rights issue that ultimately raised $3,628,256 (before costs) on 26 November 2019
through a non-renounceable rights issue of 181,412,807 shares at $0.02 to existing shareholders, sophisticated and
professional investors.
On 10 December 2019, the consolidated entity issued an additional 2,500,000 shares as payment for consideration for
professional investor relation services. The shares have been valued at the fair value on the date of issue.
Capital risk management
The consolidated entity's objectives when managing capital is to safeguard its ability to continue as a going concern, so
that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital
structure to reduce the cost of capital.
Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is
calculated as total borrowings less cash and cash equivalents.
In order to maintain or adjust the capital structure, the consolidated entity may adjust the amount of dividends paid to
shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.
The consolidated entity would look to raise capital when an opportunity to invest in a business or company was seen
as value adding relative to the current consolidated entity's share price at the time of the investment. The consolidated
entity is not actively pursuing additional investments in the short-term as it continues to integrate and grow its existing
businesses in order to maximise synergies.
Note 7. Equity – reserves
Consolidated
2019
A$
2018
A$
Foreign currency translation reserve
Share based & option reserve
32,662
681,816
102,946
1,796,992
Total
714,478
1,899,938
Foreign currency translation reserve
The reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign
operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net investments in foreign
operations.
9
Imagion Biosystems Limited
Notes to the Financial Statements
For the year ended 31 December 2019
Note 7. Equity - reserves (continued)
Movements in reserves
Movements in each class of reserve during the current and previous financial year are set out below:
Consolidated
Share
based
payment
and
option
reserve
A$
Foreign
currency
reserve
A$
Total
A$
Balance at 1 January 2018
623,927
514,943
1,138,870
Movements in revaluation of foreign currency through translation reserve
Share based payments for key management, non-executive directors and
employees
Balance at 31 December 2018
1,173,065
(411,997)
-
(411,997)
1,173,065
1,796,992
102,946
1,899,938
Movements in revaluation of foreign currency through translation reserve
Share based payments for key management, non-executive directors,
employees and third parties
Conversion to share capital
-
(70,284)
(70,284)
(954,160)
(161,016)
-
(954,160)
(161,016)
Balance at 31 December 2019
681,816
32,662
714,478
Note 8. Accumulated Losses
Consolidated
2019
2018
A$
A$
Accumulated Losses at the beginning of the financial year
Losses after income tax expense for the year
(31,213,035) (22,873,022)
(3,432,506) (8,340,013)
Accumulated Losses at the end of the financial year
(34,645,541) (31,213,035)
10
Imagion Biosystems Limited
Notes to the Financial Statements
For the year ended 31 December 2019
Note 9. Reconciliation of loss after income tax to net cash flows from operating activities
Consolidated
2019
2018
$
$
Loss after income tax expense for the year
Adjustments for:
Depreciation expense
Refundable Deposit
Fair value adjustment
Foreign exchange loss
Share based payments expense
Direct Equity Raising Costs
Collaboration Expenses
Interest
Bad Debts
Equity Settled Payments
Changes in operating assets and liabilities:
Trade and other receivables
Prepayments
Trade and other payables
Monies in trust
Net cash used in operating activities
11
(3,432,506)
(8,340,013)
141,988
123,112
32,837
(940,754)
7,882
5,657
5,188
180,852
(3,875,745)
213,791
(123,112)
(140,036)
(444,892)
837,133
(57,894)
869,811
(7,185,212)
24,192
(45,092)
(298,909)
13,509
(44,583)
287,670
371,450
3,465
(4,182,045)
(6,567,210)
Imagion Biosystems Limited
Notes to the Financial Statements
For the year ended 31 December 2019
Note 10. Earnings per share
Consolidated
2019
A$
2018
A$
Loss after income tax
(3,432,506)
(8,340,013)
Loss after income tax attributable to the owners of Imagion Biosystems Limited
(3,432,506)
(8,340,013)
Number
Weighted average number of ordinary shares used in calculating basic earnings per
share
Weighted average number of ordinary shares used in calculating diluted earnings per
share
Basic earnings per share
Diluted earnings per share
12
342,221,471 220,883,627
342,221,471 220,883,627
Cents
Cents
(0.0100)
(0.0100)
(0.0378)
(0.0378)
Share your feedback
Discover